evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

33 questions · 35 findings · 2 reviews · Dementia and Cognitive Improvement

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 32 · 91.4%High 3 · 8.6%

Donepezil 23 mg/day vs donepezil 10 mg/day

Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease

Donepezil 23 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 10 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 23 mg/day vs donepezil 10 mg/day

Secondary outcome: acceptability of treatment · people with Alzheimer's disease

Donepezil 23 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 10 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 23 mg/day vs donepezil 10 mg/day

Risk for at least one adverse event per patient · people with Alzheimer's disease

Donepezil 23 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 10 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs donepezil 5 mg/day

Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease

Donepezil 10 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 5 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs donepezil 5 mg/day

Secondary outcome: acceptability of treatment · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 5 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs donepezil 5 mg/day

Risk for at least one adverse event per patient · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 5 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 5 mg vs placebo

Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (high certainty).

1 finding from 1 review

Donepezil 5 mg vs placebo

Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Donepezil 5 mg vs placebo

Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with severe Alzheimer's disease

Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).

1 finding from 1 review